Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Dow
AstraZeneca
Moodys
Express Scripts

Last Updated: January 29, 2022

Volunteer for clinical trials for JEVTANA KIT at ClinicalTrialExchange

DrugPatentWatch Database Preview

JEVTANA KIT Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Jevtana Kit, and when can generic versions of Jevtana Kit launch?

Jevtana Kit is a drug marketed by Sanofi Aventis Us and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and nineteen patent family members in sixty-one countries.

The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cabazitaxel profile page.

DrugPatentWatch® Generic Entry Outlook for Jevtana Kit

Jevtana Kit was eligible for patent challenges on June 17, 2014.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 10, 2026. This may change due to patent challenges or generic licensing.

There have been nine patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are five tentative approvals for the generic drug (cabazitaxel), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for JEVTANA KIT
DrugPatentWatch® Estimated Generic Entry Opportunity Date for JEVTANA KIT
Generic Entry Date for JEVTANA KIT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for JEVTANA KIT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Andrew J. Armstrong, MDPhase 2
Janssen PharmaceuticaPhase 2
Prospect Creek FoundationPhase 1

See all JEVTANA KIT clinical trials

Paragraph IV (Patent) Challenges for JEVTANA KIT
Tradename Dosage Ingredient NDA Submissiondate
JEVTANA KIT SOLUTION;INTRAVENOUS cabazitaxel 201023 2014-06-17

US Patents and Regulatory Information for JEVTANA KIT

JEVTANA KIT is protected by five US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of JEVTANA KIT is ⤷  Try it Free.

This potential generic entry date is based on patent ⤷  Try it Free.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting JEVTANA KIT

Antitumoral use of cabazitaxel
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING AS A 3 WEEK CYCLE CABAZITAXEL AFTER 5 MG DEXCHLORPHENIRAMINE, 8 MG DEXAMETHASONE, AND AN H2-AGONIST

Antitumoral use of cabazitaxel
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING 20 TO 25 MG/M2 CABAZITAXEL AFTER A PREMEDICATION REGIMEN THAT INCLUDES AN H2-ANTAGONIST

Taxoids, their preparation and pharmaceutical compositions containing them
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Acetone solvate of dimethoxy docetaxel and its process of preparation
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Antitumoral use of cabazitaxel
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

FDA Regulatory Exclusivity protecting JEVTANA KIT

CLINICAL TRIAL STUDY RESULTS
Exclusivity Expiration: ⤷  Try it Free

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for JEVTANA KIT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 ⤷  Try it Free ⤷  Try it Free
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 ⤷  Try it Free ⤷  Try it Free
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 ⤷  Try it Free ⤷  Try it Free
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 ⤷  Try it Free ⤷  Try it Free
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 ⤷  Try it Free ⤷  Try it Free
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for JEVTANA KIT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1667986 C20130017 00077 Estonia ⤷  Try it Free PRODUCT NAME: KABASITAKSEEL;REG NO/DATE: K(2011)1888 LOPLIK 17.03.2011
1667986 28/2013 Austria ⤷  Try it Free PRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317
1667986 C01667986/01 Switzerland ⤷  Try it Free PRODUCT NAME: CABAZITAXELUM; REGISTRATION NO/DATE: SWISSMEDIC 61543 06.04.2011
1667986 636 Finland ⤷  Try it Free
1667986 C300595 Netherlands ⤷  Try it Free PRODUCT NAME: CABAZITAXEL ACETONAAT; REGISTRATION NO/DATE: EU/1/11/676/001 20110317
1667986 SPC/GB13/042 United Kingdom ⤷  Try it Free PRODUCT NAME: CABAZITAXEL IN THE FORM OF THE ACETONE SOLVATE; REGISTERED: UK EU/1/11/676/001 20110317
1667986 2013C/036 Belgium ⤷  Try it Free DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CESSION
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Mallinckrodt
Dow
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.